MATTHEW L SHERMAN, M.D.
Osteopathic Medicine at Sidney St, Cambridge, MA
License number
Massachusetts 50894
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
2
149 Sidney St, Cambridge, MA 02139
33 Janet Rd, Newton, MA 02459
33 Janet Rd, Newton, MA 02459
Phone
(617) 576-2220
Organization information
See more information about MATTHEW L SHERMAN at bizstanding.comMatthew L Sherman MD
87 Cambridgepark Dr, Cambridge, MA 02140
Industry:
Medical Doctor's Office
Medical Doctor, Principal:
Matthew L. Sherman (Medical Doctor, Principal)
Professional information
Treatment Of Kaposis Sarcoma With Il-12
US Patent:
6423308, Jul 23, 2002
Filed:
Sep 15, 1999
Appl. No.:
09/396931
Inventors:
Robert Yarchoan - Bethesda MD
James M. Pluda - Gaithersburg MD
Kathleen Wyvill - Upper Marlboro MD
Jill Lietzau - Columbia MD
Gene M. Shearer - Bethesda MD
Ellen Feigal - N. Potomac MD
Giovanna Tosato - Bethesda MD
Richard Little - Washington DC
Matthew L. Sherman - Newton MA
James M. Pluda - Gaithersburg MD
Kathleen Wyvill - Upper Marlboro MD
Jill Lietzau - Columbia MD
Gene M. Shearer - Bethesda MD
Ellen Feigal - N. Potomac MD
Giovanna Tosato - Bethesda MD
Richard Little - Washington DC
Matthew L. Sherman - Newton MA
Assignee:
Wyeth - Madison NJ
The United States of America as represented by the Department of Health and Human Services - Washington DC
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
A61K 4500
US Classification:
424 852, 424 851
Abstract:
Methods are provided for using IL-12 to treat Kaposis sarcoma (KS), particularly AIDS-associated KS.
Bis(Thio-Hydrazide Amides) For Treatment Of Hyperplasia
US Patent:
2006014, Jun 29, 2006
Filed:
Sep 14, 2005
Appl. No.:
11/226929
Inventors:
Matthew Sherman - Newton MA, US
Farid Vaghefi - Burlington MA, US
Lan Chen - Lexington MA, US
Farid Vaghefi - Burlington MA, US
Lan Chen - Lexington MA, US
International Classification:
A61K 31/16
US Classification:
514599000
Abstract:
Methods and medical devices for treating a proliferative disorder in a subject, e.g., restenosis in a blood vessel that has been implanted with a stent, employ a bis(thio-hydrazide amide) represented by Structural Formula I or a pharmaceutically acceptable salt or solvate thereof.
Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group. R-Rare independently —H, an optionally substituted aliphatic group, an optionally substituted aryl group, or Rand Rtaken together with the carbon and nitrogen atoms to which they are bonded, and/or Rand Rtaken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R-Rare independently —H, an optionally substituted aliphatic group, or an optionally substituted aryl group. Z is O or S.
Methods For Dosing An Actriib Antagonist And Monitoring Of Treated Patients
US Patent:
2010000, Jan 14, 2010
Filed:
Jun 26, 2009
Appl. No.:
12/459205
Inventors:
Matthew L. Sherman - Newton MA, US
Niels Borgstein - Medfield MA, US
Niels Borgstein - Medfield MA, US
Assignee:
Acceleron Pharma Inc. - Cambridge MA
International Classification:
A61K 39/395, C12Q 1/02, G01N 33/20, A61K 38/16, A61P 21/00, A61P 19/00
US Classification:
4241341, 435 29, 436 84, 4241391, 514 12
Abstract:
In certain aspects, the present invention provides methods for dosing a patient with an ActRIIb antagonist and methods for managing patients treated with an ActRIIb anatagonist. In certain aspects, the methods involve measuring one or more hematologic parameters in a patient.
Alk1 Antagonists And Their Uses In Treating Renal Cell Carcinoma
US Patent:
2013020, Aug 8, 2013
Filed:
Feb 1, 2013
Appl. No.:
13/757672
Inventors:
Rupal S. BHATT - Roslindale MA, US
Ravindra Kumar - Acton MA, US
James W. Mier - Brookline MA, US
Robert Pearsall - Woburn MA, US
Matthew Sherman - Newton MA, US
Nicolas Solban - Brighton MA, US
Ravindra Kumar - Acton MA, US
James W. Mier - Brookline MA, US
Robert Pearsall - Woburn MA, US
Matthew Sherman - Newton MA, US
Nicolas Solban - Brighton MA, US
International Classification:
A61K 38/45, A61K 31/404, A61K 31/44, A61K 31/436, A61K 31/4439, A61K 31/4709, A61K 31/517, A61K 39/395, A61K 31/506
US Classification:
4241341, 424 945, 4241391
Abstract:
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit tumor growth of renal cell carcinoma (RCC) in vivo. In additional aspects the disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of ALK1 dramatically increases the ability of a standard of care receptor tyrosine kinase inhibitor to inhibit RCC tumor growth in vivo.
Antagonists Of Actriib And Uses For Increasing Red Blood Cell Levels
US Patent:
2012000, Jan 5, 2012
Filed:
Aug 25, 2011
Appl. No.:
13/218264
Inventors:
Matthew L. Sherman - Newton MA, US
Jasbir Seehra - Lexington MA, US
Niels Borgstein - Medfield MA, US
Jasbir Seehra - Lexington MA, US
Niels Borgstein - Medfield MA, US
Assignee:
Acceleron Pharma Inc. - Cambridge MA
International Classification:
A61K 39/395, A61P 7/06, A61K 38/18, A61P 7/00, A61K 38/22, A61K 38/17
US Classification:
4241331, 4241721, 514 97, 514 89, 514 135
Abstract:
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Activin-Actriia Antagonists For Inhibiting Germ Cell Maturation
US Patent:
2013019, Aug 1, 2013
Filed:
Jan 30, 2013
Appl. No.:
13/754234
Inventors:
Jasbir Seehra - Lexington MA, US
Matthew L. Sherman - Newton MA, US
Matthew L. Sherman - Newton MA, US
Assignee:
ACCELERON PHARMA, INC. - Cambridge MA
International Classification:
C12N 9/12
US Classification:
4241341
Abstract:
In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.
Activin-Actrii Antagonists And Uses For Increasing Red Blood Cell Levels
US Patent:
8007809, Aug 30, 2011
Filed:
Sep 29, 2008
Appl. No.:
12/286333
Inventors:
Matthew L. Sherman - Newton MA, US
Assignee:
Acceleron Pharma Inc. - Cambridge MA
International Classification:
A61K 39/00, A61K 38/00
US Classification:
4241851, 514 135, 4241921
Abstract:
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Methods For Treating Fatty Liver Disease
US Patent:
2011012, Jun 2, 2011
Filed:
Nov 3, 2010
Appl. No.:
12/939084
Inventors:
Alan Koncarevic - Boston MA, US
Jennifer Lachey - Arlington MA, US
Jasbir Seehra - Lexington MA, US
Matthew L. Sherman - Newton MA, US
Jennifer Lachey - Arlington MA, US
Jasbir Seehra - Lexington MA, US
Matthew L. Sherman - Newton MA, US
Assignee:
Acceleron Pharma Inc. - Cambridge MA
International Classification:
A61K 39/395, A61K 38/16, A61P 1/16, A61K 31/7088, A61K 38/18
US Classification:
4241341, 514 213, 514 212, 4241721, 514 44 A, 514 76
Abstract:
In certain aspects, the present invention provides compositions and methods for treating fatty liver disease by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies and anti-activin A or B antibodies. A variety of hepatic and metabolic disorders may be improved by treating fatty liver disease.
Activin-Actrii Antagonists And Uses For Increasing Red Blood Cell Levels
US Patent:
7988973, Aug 2, 2011
Filed:
Dec 18, 2007
Appl. No.:
12/002872
Inventors:
Matthew L. Sherman - Newton MA, US
Assignee:
Acceleron Pharma Inc. - Cambridge MA
International Classification:
A61K 39/00, A61K 38/00
US Classification:
4241851, 514 135, 4241921
Abstract:
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Activin-Actriia Antagonists And Uses For Decreasing Or Inhibiting Fsh Secretion
US Patent:
7960343, Jun 14, 2011
Filed:
Sep 17, 2008
Appl. No.:
12/284112
Inventors:
John Knopf - Carlisle MA, US
Jasbir Seehra - Lexington MA, US
Matthew L. Sherman - Newton MA, US
Jasbir Seehra - Lexington MA, US
Matthew L. Sherman - Newton MA, US
Assignee:
Acceleron Pharma Inc. - Cambridge MA
International Classification:
A61K 38/00
US Classification:
514 97
Abstract:
In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.